-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – TNX-1900 in Migraine
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TNX-1900 in Migraine report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TNX-1900 in Migraine Drug Details: Oxytocin (TI-001) is under development for the treatment...
-
Product Insights
Skin And Skin Structure Infections (SSSI) Caused By Bacteria – Drugs In Development, 2023
Global Markets Direct’s, ‘Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Drugs In Development, 2023’, provides an overview of the Skin And Skin Structure Infections (SSSI) Caused By Bacteria pipeline landscape. The report provides comprehensive information on the therapeutics under development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological...
-
Product Insights
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Methicillin-Resistant Staphylococcus Aureus (MRSA) Clinical Trial Report Overview A total of 418 MRSA clinical trials were conducted as of January 2024. The MRSA clinical trial report provides a comprehensive understanding of the MRSA clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions ·       Asia-Pacific ·       Europe ·       ...
-
Product Insights
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Drugs In Development, 2023’, provides an overview of the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EXS-617 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EXS-617 in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EXS-617 in Colorectal Cancer Drug Details: EXS-617 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gemcitabine Hydrochloride in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gemcitabine Hydrochloride in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gemcitabine Hydrochloride in Solid Tumor Drug Details: Gemcitabine hydrochloride (D07001-F4)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BEI-103 in Glioblastoma Multiforme (GBM)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.BEI-103 in Glioblastoma Multiforme (GBM)Drug Details:BEI-103 is under development for the treatment of glioblastoma. The drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Oxytocin in Prader-Willi Syndrome (PWS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Oxytocin in Prader-Willi Syndrome (PWS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Oxytocin in Prader-Willi Syndrome (PWS) Drug Details: Oxytocin is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NC-525 in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NC-525 in Refractory Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NC-525 in Refractory Acute Myeloid Leukemia Drug Details: NC-525...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MRX-8 in Gram-Negative Bacterial Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MRX-8 in Gram-Negative Bacterial Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.MRX-8 in Gram-Negative Bacterial InfectionsDrug Details:MRX-8 is under development for the treatment...